New York Times business editor Ellen Pollock sent out the following announcement on Thursday:
The race to develop and distribute vaccines and treatments for Covid-19 might be the most pressing challenge facing the world right now.
We are thrilled to announce that Rebecca Robbins is joining the Business desk to cover that race. She will be part of the Business investigations team and closely collaborating with our colleagues in Health on pharmaceutical coverage.
Rebecca joins us from Stat News, where she distinguished herself with her investigative reporting on topics including artificial intelligence and the unusual financial dealings of Patrick Soon-Shiong. She also co-hosted a weekly podcast on the biotech industry. Most recently, she was part of a team at Stat that was first to report that AstraZeneca had halted trials of its promising Covid-19 vaccine after a participant fell ill.
Before joining Stat in 2015, she had internships at The Washington Post, The Hartford Courant and The Santa Barbara Independent (her hometown alt-weekly), and she was the managing editor of The Harvard Crimson.
Please join us in welcoming Rebecca to The Times.
